TENX TENAX THERAPEUTICS, INC. Insider Trading

CMO Rich Stuart buys 5,000 TENX shares in 2 transactions for $50,792.50 ($10.10–$10.22), raising stake to 5,266 shares.

Rich Stuart, Chief Medical Officer of Tenax Therapeutics, executed 2 separate purchases totaling 5,000 shares for $50,792.50 over consecutive trading days (2025-12-08 and 2025-12-09), bringing his holdings from 266 shares to 5,266 shares—a +1879.7% increase in position size. The purchases occurred at $10.10 and $10.22, near the upper end of the 52-week range ($5.10–$10.30), while the current price of $9.82 is -4.7% below the 52-week high. The company reported zero revenue in its latest quarter and negative net income of $-15,804,000.00, indicating a pre-revenue stage business burning cash. These large purchases by a C-suite executive in a financially distressed biotech follow three prior buy transactions at this ticker within the preceding week, establishing a pattern of accumulation despite the company's lack of profitability and revenue generation.

CMO Rich Stuart purchases 5,000 shares across 3 days (Dec 2-4) at blended avg $9.12; stock at 52-week high of $9.65.

Rich Stuart (Chief Medical Officer) executed 3 separate purchases totaling 5,000 shares for $45,621.80 between December 2–4, 2025, at prices ranging from $9.01 to $9.20 per share. The buys occur as the stock trades at its 52-week high of $9.65, with the broader context showing a 30-day price increase of +36.1% and a 90-day increase of +61.0%. However, the company's fundamental position remains precarious: revenues in the latest quarter are $0.00, net income is negative at $-15,804,000.00, and the market capitalization stands at $60,250,498.75. This executive accumulation of shares occurs in the context of an unprofitable biopharmaceutical company that has experienced recent price momentum but lacks current revenue generation.

CEO Giordano Thomas buys 2,605 shares for $19,999.78 across 3 transactions; cluster pattern with 2 other insiders buying within 14 days.

CEO Giordano Thomas purchased 2,605 shares across three separate transactions at an average price of $7.68 per share between November 18–20, 2025, with the stock currently trading at $7.70. This filing reflects a cluster buy pattern, with 2 other insiders also purchasing shares within the past 14 days, suggesting coordinated or near-simultaneous confidence at current price levels. Notably, the company is unprofitable with net income of $-15.8M over its most recent full fiscal year and zero revenue in the latest quarter, yet the stock has appreciated 28.3% over the past 90 days and 6.6% over the past 30 days. The CEO's establishment of an initial 2.6K share position may warrant scrutiny given the fundamental profile, though the clustering of insider purchases across multiple executives deserves investor attention.

Interim CFO McGauley buys 8,000 shares at $7.27 blended average; co-insider cluster buy pattern emerges at unprofitable biotech.

Thomas McGauley, Interim CFO of Tenax Therapeutics, executed 3 separate purchases totaling 8,000 shares for $58,164.00 on 2025-11-17 at prices ranging from $7.23 to $7.35. The buy-in brings his post-transaction holding to 5,000 shares from a negative pre-transaction position of -3,000 shares, suggesting a settlement or covering of a prior short/obligation. The 30-day price action shows +9.2% gains and 90-day performance of +21.2%, placing the current $7.32 price near recent highs at -6.5% from the 52-week high of $7.83. Most notably, 2 other insiders also purchased within the past 14 days, establishing a cluster buy pattern. However, the fundamental backdrop remains highly challenged: the company reported $0.00 revenue in the latest quarter and carries a net loss of $-15,804,000.00 with an unprofitable fiscal year, and the market cap stands at only $45,702,969.00. The clustering of insider purchases at a biotech with zero revenue and ongoing significant losses warrants scrutiny into the specific circumstances—whether this reflects a planned financing, clinical catalyst, or other material event.

Director Almenoff purchases 1,993 shares in 2 transactions at blended avg $7.50; cluster buy with 2 other insiders in past 14 days

Director June Sherie Almenoff purchased 1,993 shares across 2 separate transactions totaling $14,944.78 at an average price of $7.50, establishing an initial stake in TENX. The purchase occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, which may indicate aligned appetite for the stock at current levels. Notably, TENX is unprofitable with a net income of $-15,804,000.00 and zero revenue in the latest quarter, operating from a market cap of $45,702,969.00. The stock is currently -6.5% from its 52-week high and has shown positive momentum over 30 and 90 days (+9.2% and +21.2% respectively), though Almenoff's cross-ticker track record shows an average 90-day return of +5.8% across all prior buys with a 100.00% win rate. The convergence of multiple insiders entering the stock during a recovery phase and amid significant operational losses warrants scrutiny of the company's near-term developments and capital position.

Director PROEHL bought 1,666 shares of TENX on 2024-08-08; holdings rose from 1 to 1,667 shares (+166600.0%)

PROEHL GERALD T, a director, acquired 1,666 shares on 2024-08-08, increasing his holdings from 1 share to 1,667 shares. The transaction value is recorded as $0.00, indicating either a non-cash acquisition (e.g., restricted stock grant, warrant exercise, or stock dividend) or a data-reporting anomaly. The company presents concerning fundamentals: Revenue is $0.00 for the latest quarter with -100.0% annual revenue growth, net income sits at $3,798,840.00 ($3.8M) against a $8.1M market cap, and the P/E is 0.80, signaling a company in severe contraction. The stock has declined 91.6% from its 52-week high of $49.60 to the current price of $4.14, though it has recovered 29.8% over the past 30 days. Without clarity on the transaction mechanism (price, cash vs. non-cash consideration), investors cannot determine whether this represents a deliberate capital commitment or a routine corporate action such as vesting or dividend reinvestment.

Director Davidson buys 2,500 shares of TENX; holdings rise 656.2% to 2,881 shares; stock down 91.6% from 52-week high.

Director Michael H. Davidson purchased 2,500 shares of Tenax Therapeutics on 2024-08-08, a material increase to his position holdings from 381 shares to 2,881 shares (+656.2% increase in his stake). The purchase occurred at a time when the stock trades at $4.14, down 91.6% from its 52-week high of $49.60, though the stock has recovered 29.8% over the prior 30 days and 15.5% over 90 days. The company's fundamentals present a notable discontinuity: revenue was $0.00 in the latest quarter with annual revenue growth of -100.0%, yet net income was reported at $3,798,840.00, creating an unusual earnings profile for a micro-cap ($8.1M market cap) with a P/E of 0.80. The buy activity is noteworthy given both the magnitude of the relative position increase and the company's shifted revenue trajectory, though without scheduled trading plan disclosure or transaction price context, the circumstances warrant examination.